VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis
Effects on adhesion molecules of immune cells might contribute to the mode of action of interferon-β (IFN-β) in multiple sclerosis (MS). We have serially monitored the cell surface expression of integrins CD49d (VLA-4) and CD11a (LFA-1) on fresh T lymphocyte subpopulations from 5 MS patients monthly...
Gespeichert in:
| Veröffentlicht in: | Journal of neuroimmunology 2000-11, Vol.111 (1), p.186-194 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 194 |
|---|---|
| container_issue | 1 |
| container_start_page | 186 |
| container_title | Journal of neuroimmunology |
| container_volume | 111 |
| creator | Muraro, P.A Leist, T Bielekova, B McFarland, H.F |
| description | Effects on adhesion molecules of immune cells might contribute to the mode of action of interferon-β (IFN-β) in multiple sclerosis (MS). We have serially monitored the cell surface expression of integrins CD49d (VLA-4) and CD11a (LFA-1) on fresh T lymphocyte subpopulations from 5 MS patients monthly for 2 months prior to treatment and for 3 months on treatment with IFN-β1b. In parallel, we assessed inflammatory disease activity by monthly contrast-enhanced magnetic resonance imaging (MRI). IFN-β treatment specifically downregulated CD49d expression on CD8+ and CD4+/CD45RO+ ‘memory’ T lymphocytes and differentially modulated the proportion of CD4+, CD8+ and CD27+ T cells. These effects may play an important role in the reduction of central nervous system cell trafficking and inflammation in MS. |
| doi_str_mv | 10.1016/S0165-5728(00)00362-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72392609</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165572800003623</els_id><sourcerecordid>72392609</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-aaf63aae855b110c3cb3f75bc9ccffdd31c05eb8d6192ddfe99b433e4cf8fbfb3</originalsourceid><addsrcrecordid>eNqFkctOAyEUhonR2Hp5BA0ro4uxMMx1ZZp6TZq4sLolDBxazHRmhBnNvJYP4jNJL9FlN4cT-A4__D9CZ5RcU0KT0YsvcRCnYXZJyBUhLAkDtoeGNEvDIItCuo-Gf8gAHTn3TgiNWZQfogGlJGEZS4dIvU3HQTSa3Ea5wqr-qizMu1K0oHBd4caape9muOyXzaKWfQsOq86aao5N1YLVYOsq-PnG7QKsaHq_i5dd2ZqmBOxk6Y-dcSfoQIvSwel2PUav93ezyWMwfX54moyngWR52AZC6IQJAVkcF_6FksmC6TQuZC6l1koxKkkMRaYSmodKacjzImIMIqkzXeiCHaOLzb2NrT86cC1fGiehLEUFded4GnqdhOQ7QZqmNCNrMN6A0n_EWdB8ZYmwPaeEr3Lg6xz4ymROCF_nwJmfO98KdIV38H9qa7wHbjYAeD8-DVjupIFKgjIWZMtVbXZI_AI6HZpZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17718009</pqid></control><display><type>article</type><title>VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Muraro, P.A ; Leist, T ; Bielekova, B ; McFarland, H.F</creator><creatorcontrib>Muraro, P.A ; Leist, T ; Bielekova, B ; McFarland, H.F</creatorcontrib><description>Effects on adhesion molecules of immune cells might contribute to the mode of action of interferon-β (IFN-β) in multiple sclerosis (MS). We have serially monitored the cell surface expression of integrins CD49d (VLA-4) and CD11a (LFA-1) on fresh T lymphocyte subpopulations from 5 MS patients monthly for 2 months prior to treatment and for 3 months on treatment with IFN-β1b. In parallel, we assessed inflammatory disease activity by monthly contrast-enhanced magnetic resonance imaging (MRI). IFN-β treatment specifically downregulated CD49d expression on CD8+ and CD4+/CD45RO+ ‘memory’ T lymphocytes and differentially modulated the proportion of CD4+, CD8+ and CD27+ T cells. These effects may play an important role in the reduction of central nervous system cell trafficking and inflammation in MS.</description><identifier>ISSN: 0165-5728</identifier><identifier>EISSN: 1872-8421</identifier><identifier>DOI: 10.1016/S0165-5728(00)00362-3</identifier><identifier>PMID: 11063837</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adhesion molecules ; Adjuvants, Immunologic - administration & dosage ; Antigens, CD - immunology ; Antigens, CD - metabolism ; b-Interferon ; Biomarkers ; CD4 Antigens - analysis ; CD49d antigen ; CD58 Antigens - analysis ; CD8 Antigens - analysis ; Down-Regulation - immunology ; Female ; Flow Cytometry ; HLA-DR Antigens - analysis ; Humans ; Immunologic Memory - drug effects ; Immunologic Memory - immunology ; Integrin alpha4 ; Integrin alpha4beta1 ; Integrin beta1 - analysis ; Integrins - immunology ; Integrins - metabolism ; Intercellular Adhesion Molecule-1 - analysis ; Interferon-beta - administration & dosage ; Interferon-β ; Leukocyte Common Antigens - analysis ; Lymphocyte Function-Associated Antigen-1 - analysis ; Magnetic Resonance Imaging ; Male ; Multiple sclerosis ; Multiple Sclerosis, Relapsing-Remitting - diagnosis ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Multiple Sclerosis, Relapsing-Remitting - immunology ; Receptors, Lymphocyte Homing - immunology ; Receptors, Lymphocyte Homing - metabolism ; T lymphocytes ; T-Lymphocytes - chemistry ; T-Lymphocytes - immunology ; T-Lymphocytes - metabolism ; Tumor Necrosis Factor Receptor Superfamily, Member 7 - analysis ; VLA-4</subject><ispartof>Journal of neuroimmunology, 2000-11, Vol.111 (1), p.186-194</ispartof><rights>2000 Elsevier Science B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-aaf63aae855b110c3cb3f75bc9ccffdd31c05eb8d6192ddfe99b433e4cf8fbfb3</citedby><cites>FETCH-LOGICAL-c392t-aaf63aae855b110c3cb3f75bc9ccffdd31c05eb8d6192ddfe99b433e4cf8fbfb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0165-5728(00)00362-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11063837$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Muraro, P.A</creatorcontrib><creatorcontrib>Leist, T</creatorcontrib><creatorcontrib>Bielekova, B</creatorcontrib><creatorcontrib>McFarland, H.F</creatorcontrib><title>VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis</title><title>Journal of neuroimmunology</title><addtitle>J Neuroimmunol</addtitle><description>Effects on adhesion molecules of immune cells might contribute to the mode of action of interferon-β (IFN-β) in multiple sclerosis (MS). We have serially monitored the cell surface expression of integrins CD49d (VLA-4) and CD11a (LFA-1) on fresh T lymphocyte subpopulations from 5 MS patients monthly for 2 months prior to treatment and for 3 months on treatment with IFN-β1b. In parallel, we assessed inflammatory disease activity by monthly contrast-enhanced magnetic resonance imaging (MRI). IFN-β treatment specifically downregulated CD49d expression on CD8+ and CD4+/CD45RO+ ‘memory’ T lymphocytes and differentially modulated the proportion of CD4+, CD8+ and CD27+ T cells. These effects may play an important role in the reduction of central nervous system cell trafficking and inflammation in MS.</description><subject>Adhesion molecules</subject><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>Antigens, CD - immunology</subject><subject>Antigens, CD - metabolism</subject><subject>b-Interferon</subject><subject>Biomarkers</subject><subject>CD4 Antigens - analysis</subject><subject>CD49d antigen</subject><subject>CD58 Antigens - analysis</subject><subject>CD8 Antigens - analysis</subject><subject>Down-Regulation - immunology</subject><subject>Female</subject><subject>Flow Cytometry</subject><subject>HLA-DR Antigens - analysis</subject><subject>Humans</subject><subject>Immunologic Memory - drug effects</subject><subject>Immunologic Memory - immunology</subject><subject>Integrin alpha4</subject><subject>Integrin alpha4beta1</subject><subject>Integrin beta1 - analysis</subject><subject>Integrins - immunology</subject><subject>Integrins - metabolism</subject><subject>Intercellular Adhesion Molecule-1 - analysis</subject><subject>Interferon-beta - administration & dosage</subject><subject>Interferon-β</subject><subject>Leukocyte Common Antigens - analysis</subject><subject>Lymphocyte Function-Associated Antigen-1 - analysis</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - diagnosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Multiple Sclerosis, Relapsing-Remitting - immunology</subject><subject>Receptors, Lymphocyte Homing - immunology</subject><subject>Receptors, Lymphocyte Homing - metabolism</subject><subject>T lymphocytes</subject><subject>T-Lymphocytes - chemistry</subject><subject>T-Lymphocytes - immunology</subject><subject>T-Lymphocytes - metabolism</subject><subject>Tumor Necrosis Factor Receptor Superfamily, Member 7 - analysis</subject><subject>VLA-4</subject><issn>0165-5728</issn><issn>1872-8421</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctOAyEUhonR2Hp5BA0ro4uxMMx1ZZp6TZq4sLolDBxazHRmhBnNvJYP4jNJL9FlN4cT-A4__D9CZ5RcU0KT0YsvcRCnYXZJyBUhLAkDtoeGNEvDIItCuo-Gf8gAHTn3TgiNWZQfogGlJGEZS4dIvU3HQTSa3Ea5wqr-qizMu1K0oHBd4caape9muOyXzaKWfQsOq86aao5N1YLVYOsq-PnG7QKsaHq_i5dd2ZqmBOxk6Y-dcSfoQIvSwel2PUav93ezyWMwfX54moyngWR52AZC6IQJAVkcF_6FksmC6TQuZC6l1koxKkkMRaYSmodKacjzImIMIqkzXeiCHaOLzb2NrT86cC1fGiehLEUFded4GnqdhOQ7QZqmNCNrMN6A0n_EWdB8ZYmwPaeEr3Lg6xz4ymROCF_nwJmfO98KdIV38H9qa7wHbjYAeD8-DVjupIFKgjIWZMtVbXZI_AI6HZpZ</recordid><startdate>20001101</startdate><enddate>20001101</enddate><creator>Muraro, P.A</creator><creator>Leist, T</creator><creator>Bielekova, B</creator><creator>McFarland, H.F</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20001101</creationdate><title>VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis</title><author>Muraro, P.A ; Leist, T ; Bielekova, B ; McFarland, H.F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-aaf63aae855b110c3cb3f75bc9ccffdd31c05eb8d6192ddfe99b433e4cf8fbfb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adhesion molecules</topic><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>Antigens, CD - immunology</topic><topic>Antigens, CD - metabolism</topic><topic>b-Interferon</topic><topic>Biomarkers</topic><topic>CD4 Antigens - analysis</topic><topic>CD49d antigen</topic><topic>CD58 Antigens - analysis</topic><topic>CD8 Antigens - analysis</topic><topic>Down-Regulation - immunology</topic><topic>Female</topic><topic>Flow Cytometry</topic><topic>HLA-DR Antigens - analysis</topic><topic>Humans</topic><topic>Immunologic Memory - drug effects</topic><topic>Immunologic Memory - immunology</topic><topic>Integrin alpha4</topic><topic>Integrin alpha4beta1</topic><topic>Integrin beta1 - analysis</topic><topic>Integrins - immunology</topic><topic>Integrins - metabolism</topic><topic>Intercellular Adhesion Molecule-1 - analysis</topic><topic>Interferon-beta - administration & dosage</topic><topic>Interferon-β</topic><topic>Leukocyte Common Antigens - analysis</topic><topic>Lymphocyte Function-Associated Antigen-1 - analysis</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - diagnosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Multiple Sclerosis, Relapsing-Remitting - immunology</topic><topic>Receptors, Lymphocyte Homing - immunology</topic><topic>Receptors, Lymphocyte Homing - metabolism</topic><topic>T lymphocytes</topic><topic>T-Lymphocytes - chemistry</topic><topic>T-Lymphocytes - immunology</topic><topic>T-Lymphocytes - metabolism</topic><topic>Tumor Necrosis Factor Receptor Superfamily, Member 7 - analysis</topic><topic>VLA-4</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Muraro, P.A</creatorcontrib><creatorcontrib>Leist, T</creatorcontrib><creatorcontrib>Bielekova, B</creatorcontrib><creatorcontrib>McFarland, H.F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuroimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Muraro, P.A</au><au>Leist, T</au><au>Bielekova, B</au><au>McFarland, H.F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis</atitle><jtitle>Journal of neuroimmunology</jtitle><addtitle>J Neuroimmunol</addtitle><date>2000-11-01</date><risdate>2000</risdate><volume>111</volume><issue>1</issue><spage>186</spage><epage>194</epage><pages>186-194</pages><issn>0165-5728</issn><eissn>1872-8421</eissn><abstract>Effects on adhesion molecules of immune cells might contribute to the mode of action of interferon-β (IFN-β) in multiple sclerosis (MS). We have serially monitored the cell surface expression of integrins CD49d (VLA-4) and CD11a (LFA-1) on fresh T lymphocyte subpopulations from 5 MS patients monthly for 2 months prior to treatment and for 3 months on treatment with IFN-β1b. In parallel, we assessed inflammatory disease activity by monthly contrast-enhanced magnetic resonance imaging (MRI). IFN-β treatment specifically downregulated CD49d expression on CD8+ and CD4+/CD45RO+ ‘memory’ T lymphocytes and differentially modulated the proportion of CD4+, CD8+ and CD27+ T cells. These effects may play an important role in the reduction of central nervous system cell trafficking and inflammation in MS.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>11063837</pmid><doi>10.1016/S0165-5728(00)00362-3</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-5728 |
| ispartof | Journal of neuroimmunology, 2000-11, Vol.111 (1), p.186-194 |
| issn | 0165-5728 1872-8421 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72392609 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adhesion molecules Adjuvants, Immunologic - administration & dosage Antigens, CD - immunology Antigens, CD - metabolism b-Interferon Biomarkers CD4 Antigens - analysis CD49d antigen CD58 Antigens - analysis CD8 Antigens - analysis Down-Regulation - immunology Female Flow Cytometry HLA-DR Antigens - analysis Humans Immunologic Memory - drug effects Immunologic Memory - immunology Integrin alpha4 Integrin alpha4beta1 Integrin beta1 - analysis Integrins - immunology Integrins - metabolism Intercellular Adhesion Molecule-1 - analysis Interferon-beta - administration & dosage Interferon-β Leukocyte Common Antigens - analysis Lymphocyte Function-Associated Antigen-1 - analysis Magnetic Resonance Imaging Male Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - diagnosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - immunology Receptors, Lymphocyte Homing - immunology Receptors, Lymphocyte Homing - metabolism T lymphocytes T-Lymphocytes - chemistry T-Lymphocytes - immunology T-Lymphocytes - metabolism Tumor Necrosis Factor Receptor Superfamily, Member 7 - analysis VLA-4 |
| title | VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T11%3A54%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=VLA-4/CD49d%20downregulated%20on%20primed%20T%20lymphocytes%20during%20interferon-%CE%B2%20therapy%20in%20multiple%20sclerosis&rft.jtitle=Journal%20of%20neuroimmunology&rft.au=Muraro,%20P.A&rft.date=2000-11-01&rft.volume=111&rft.issue=1&rft.spage=186&rft.epage=194&rft.pages=186-194&rft.issn=0165-5728&rft.eissn=1872-8421&rft_id=info:doi/10.1016/S0165-5728(00)00362-3&rft_dat=%3Cproquest_cross%3E72392609%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17718009&rft_id=info:pmid/11063837&rft_els_id=S0165572800003623&rfr_iscdi=true |